Paul Smith

1.2k total citations
26 papers, 694 citations indexed

About

Paul Smith is a scholar working on Oncology, Immunology and Rheumatology. According to data from OpenAlex, Paul Smith has authored 26 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Immunology and 8 papers in Rheumatology. Recurrent topics in Paul Smith's work include Cytokine Signaling Pathways and Interactions (10 papers), interferon and immune responses (5 papers) and Multiple Sclerosis Research Studies (5 papers). Paul Smith is often cited by papers focused on Cytokine Signaling Pathways and Interactions (10 papers), interferon and immune responses (5 papers) and Multiple Sclerosis Research Studies (5 papers). Paul Smith collaborates with scholars based in United States, Switzerland and Germany. Paul Smith's co-authors include Fiona Kuo, Michael Howell, Ashish Juvekar, Stefan Zurbruegg, Eduardo Huarte, Nicolau Beckmann, Michael T. Peel, Swamy Yeleswaram, Maryanne Covington and Mario Köster and has published in prestigious journals such as Journal of Biological Chemistry, Blood and The Journal of Immunology.

In The Last Decade

Paul Smith

26 papers receiving 690 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Smith United States 11 253 164 130 127 99 26 694
Ingrid Teige Sweden 14 556 2.2× 274 1.7× 36 0.3× 229 1.8× 175 1.8× 40 939
JT Elder United States 10 386 1.5× 98 0.6× 173 1.3× 142 1.1× 52 0.5× 13 702
Hongjiang Qiao China 20 410 1.6× 82 0.5× 170 1.3× 347 2.7× 15 0.2× 46 1.1k
Taras Lyubchenko United States 13 289 1.1× 77 0.5× 75 0.6× 137 1.1× 11 0.1× 33 596
Dirk Behrens Germany 7 463 1.8× 138 0.8× 35 0.3× 236 1.9× 124 1.3× 13 757
Hong Wei China 17 258 1.0× 86 0.5× 55 0.4× 897 7.1× 46 0.5× 32 1.2k
Constanze Schwarz Germany 8 213 0.8× 91 0.6× 84 0.6× 223 1.8× 29 0.3× 14 512
Tian Tian China 15 120 0.5× 172 1.0× 28 0.2× 291 2.3× 36 0.4× 60 771
Ayman Rezk Canada 16 670 2.6× 174 1.1× 15 0.1× 208 1.6× 241 2.4× 22 1.2k
Christopher G. Dove United States 8 425 1.7× 105 0.6× 14 0.1× 216 1.7× 51 0.5× 9 764

Countries citing papers authored by Paul Smith

Since Specialization
Citations

This map shows the geographic impact of Paul Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Smith more than expected).

Fields of papers citing papers by Paul Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Smith. The network helps show where Paul Smith may publish in the future.

Co-authorship network of co-authors of Paul Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Smith. A scholar is included among the top collaborators of Paul Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Smith. Paul Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nuesslein‐Hildesheim, Barbara, Enrico Ferrero, Catherine Huck, et al.. (2023). Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis. Journal of Neuroinflammation. 20(1). 194–194. 9 indexed citations
2.
Huarte, Eduardo, Michael T. Peel, Katherine Verbist, et al.. (2021). Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. Frontiers in Pharmacology. 12. 650295–650295. 32 indexed citations
3.
Smith, Paul, Wenqing Yao, Stacey Shepard, et al.. (2021). Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics. 13(7). 1044–1044. 17 indexed citations
4.
Huarte, Eduardo, Roddy S. O’Connor, Michael T. Peel, et al.. (2020). Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clinical Cancer Research. 26(23). 6299–6309. 67 indexed citations
5.
Yeleswaram, Swamy, Paul Smith, Timothy C. Burn, et al.. (2020). Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Clinical Immunology. 218. 108517–108517. 70 indexed citations
6.
Smith, Paul, et al.. (2019). AB0042 PRECLINICAL EVALUATION OF JAK1 SELECTIVE INHIBITORS INCB039110 AND INCB054707 AS TARGETED THERAPY OF CUTANEOUS LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 78. 1487–1487. 3 indexed citations
7.
Huck, Catherine, et al.. (2019). Low-Dose Subcutaneous Anti-CD20 Treatment Depletes Disease Relevant B Cell Subsets and Attenuates Neuroinflammation. Journal of Neuroimmune Pharmacology. 14(4). 709–719. 9 indexed citations
8.
9.
Howell, Michael, Fiona Kuo, & Paul Smith. (2019). Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Frontiers in Immunology. 10. 2342–2342. 173 indexed citations
10.
11.
Beckmann, Nicolau, E. Giorgetti, Stefan Zurbruegg, et al.. (2018). Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945. Acta Neuropathologica Communications. 6(1). 9–9. 92 indexed citations
12.
Smith, Paul, Stefan Zurbruegg, Arno Doelemeyer, et al.. (2018). Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis. Journal of Neuroimmunology. 318. 103–113. 38 indexed citations
13.
Auberson, Yves P., Emmanuelle Briard, Bettina Rudolph, et al.. (2018). PET Imaging of T Cells: Target Identification and Feasibility Assessment. ChemMedChem. 13(15). 1566–1579. 1 indexed citations
14.
Smith, Paul, Catherine Huck, Diethilde Theil, et al.. (2017). Ofatumumab Differs from Rituximab by Effectively Targeting Lymph Node B cells and Achieving Faster Post-treatment Repletion (S24.003). Neurology. 88(16_supplement). 5 indexed citations
15.
16.
17.
Harari, Daniel, Renne Abramovich, Alla L. Zozulya, et al.. (2014). Bridging the Species Divide: Transgenic Mice Humanized for Type-I Interferon Response. PLoS ONE. 9(1). e84259–e84259. 31 indexed citations
18.
Harari, Daniel, Renne Abramovich, Keren Sasson, et al.. (2014). 73. Cytokine. 70(1). 45–45. 1 indexed citations
19.
Harari, Daniel, Renne Abramovich, Keren Sasson, et al.. (2014). Enhanced in vivo efficacy of a long-life type I Interferon superagonist in a mouse model of multiple sclerosis. Journal of Neuroimmunology. 275(1-2). 219–219. 1 indexed citations
20.
Marchetti, Bianca, Maria C. Morale, J. Brouwer, et al.. (2002). Exposure to a Dysfunctional Glucocorticoid Receptor from Early Embryonic Life Programs the Resistance to Experimental Autoimmune Encephalomyelitis Via Nitric Oxide-Induced Immunosuppression. The Journal of Immunology. 168(11). 5848–5859. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ingrid Teige Breakdown of academic impact, for papers by JT Elder Breakdown of academic impact, for papers by Hongjiang Qiao Breakdown of academic impact, for papers by Taras Lyubchenko Breakdown of academic impact, for papers by Dirk Behrens Breakdown of academic impact, for papers by Hong Wei Breakdown of academic impact, for papers by Constanze Schwarz Breakdown of academic impact, for papers by Tian Tian Breakdown of academic impact, for papers by Ayman Rezk Breakdown of academic impact, for papers by Christopher G. Dove
Rankless by CCL
2026